Shanghai Fosun Pharmaceutical(Group) Co.,Ltd.’s Net Profit Dropped 3.8% in First Three Quarters of 2023

Shanghai Fosun Pharmaceutical(Group) Co.,Ltd. (上海复星医药(集团)股份有限公司) (600196.SH) reported a net profit of 2.7 billion yuan in the first three quarters of 2023, down 3.8% year-on-year.

Meanwhile, the company posted 30.7 billion yuan in revenue, down 2.9% year-on-year.

At the end of the reporting period, it had 110.8 billion yuan in total assets and 54.8 billion yuan in total liabilities, with a liability-to-asset ratio of 49.5%.